Investment Thesis
NP Life Sciences is a pre-revenue/minimal-revenue educational services company with severely negative profitability, burning cash at an unsustainable rate ($73.6K operating cash outflow against only $164.6K revenue). Despite adequate short-term liquidity, the company's persistent operating losses, negative ROE/ROA, and deteriorating financial position indicate fundamental business dysfunction with no clear path to profitability.
Strengths
- Strong short-term liquidity with 7.31x current ratio and $70.6K cash position
- Minimal debt burden with 0x debt-to-equity ratio reducing solvency risk
- Revenue growth of 13.8% YoY showing some top-line traction
Risks
- Operating cash burn of $73.6K annually is unsustainable given only $164.6K revenue; cash runway critically limited
- Negative operating margin (-0.4%), net margin (-1.8%), ROE (-17.9%), and ROA (-3.8%) indicate severe operational dysfunction
- Microscopic revenue base ($164.6K) with negative net income suggests company lacks viable business model or meaningful customer adoption
Key Metrics to Watch
- Operating cash flow trend - critical to assess sustainability; current burn rate is terminal
- Revenue trajectory and customer acquisition cost relative to sales - currently insufficient to cover operating expenses
- Path to GAAP profitability and operating margin expansion - no evidence of viable scaling model
Financial Metrics
Revenue
164.6K
Net Income
-2.9K
EPS (Diluted)
$0.00
Free Cash Flow
-73.6K
Total Assets
76.9K
Cash
70.6K
Profitability Ratios
Gross Margin
N/A
Operating Margin
-0.4%
Net Margin
-1.8%
ROE
-17.9%
ROA
-3.8%
FCF Margin
-44.7%
Balance Sheet & Liquidity
Current Ratio
7.31x
Quick Ratio
7.31x
Debt/Equity
0.00x
Debt/Assets
78.7%
Interest Coverage
-1.07x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T04:20:10.520209 |
Data as of: 2023-12-31 |
Powered by Claude AI